SEC Form 4 · accession 0001379344-26-000005
Mirum Pharmaceuticals, Inc. · MIRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurent Fischer
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 8:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001759425
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $101.00 | Jun 15, 2026 | A | 3,772 | A | — | Jun 14, 2036 | Common Stock | 3,772 | 3,772 | D |
| Deferred Stock UnitsF2 | — | Jun 15, 2026 | A | 1,980 | A | — | — | Common Stock | 1,980 | 1,980 | D |
Explanation of responses
- F1The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
- F2Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.